Mercury Laboratories Limited develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally. The company offers analgesic, anti-inflammatory, anti-pyretic, anthelmintic, antibiotic, anti-coagulant, anti-platelet, bleeding agent, anti-fungal, anti-hypertensive, anti-malarial, cardiovascular system, central nervous system, eye, gastro-intestinal system, hypoglycemic/anti-diabetic, multivitamin, protein supplement, respiratory system, anti-allergic, steroids, urinary system, uterine stimulant, and other drugs; and formulations, including tablets, oral liquids, injections, small volume parenterals, and eye/ear drops. It also provides pharmaceutical products for PCOS and uterine disorders, galactagogue, haemostat, iron, pain management, preterm labor management, antiemetic, PPI, vitamin K1, zinc supplement, vitamin D3, digestive enzyme, promolact, and childcare, as well as products for gynec, pediatric, surgeon, and physician applications. The company export its products comprising anti-inflammatory, antimalarial, digestive, hypoglycemic, multivitamin, CNS, pain management, gynec, CVS, cough and cold, miscellaneous, and other formulations, as well as antibiotic, antifungal, and antiviral formulations to approximately 25 countries, including the Philippines, Myanmar, Sri Lanka, Vietnam, Cambodia, D.R. Congo, Ghana, Nigeria, Mozambique, Zambia, Kenya, lvory Coast, Mauritania, Burundi, Togo, Guatemala, Costa Rica, Peru, Ecuador, the United Kingdom, the United States, Moldova, and Jamaica. Mercury Laboratories Limited was founded in 1962 and is headquartered in Vadodara, India.
तुलना करने के लिए मीट्रिक्स | MRCU | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधMRCUपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | 26.1x | 19.4x | −0.5x | |
PEG अनुपात | −6.52 | 0.75 | 0.00 | |
क़ीमत/बुक | 2.0x | 2.5x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 1.4x | 2.1x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 8.8% | 55.3% | |
उचित मूल्य अपसाइड | अनलॉक करें | −6.0% | 9.8% | अनलॉक करें |